LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather

H. Fontaine; C. Hezode; F. Zoulim; D. Samuel; M. Bourlière; G. Haour; C. Dorival-Mouly; V. Leroy; V. de Ledinghen; S. Lucier; D. Larrey; A. Tran; S. Metivier; Y. Benhamou; I. Hubert-Fouchard; F. Habersetzer; P. Marcellin; P. Mathurin; Laurent Alric; J. -P. Bronowicki; D. Guyader; V. Loustaud-Ratti; A. Minello; G. Riachi; I. Rosa; M. Simony; A. Diallo; F. Carrat; S Pol

doi:10.1016/S0168-8278(15)30182-3

Poster de colloque

LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather

H. Fontaine, C. Hezode, F. Zoulim, D. Samuel, M. Bourlière, G. Haour, C. Dorival-Mouly, V. Leroy, V. de Ledinghen, S. Lucier, …

The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver (Vienne, Austria, 22/04/2015)

2015

DOI: https://doi.org/10.1016/S0168-8278(15)30182-3

Résumé

sofosbuvir-based

HCV genotype 4-mono-infected

anrs CO22 hepather

Introduction:Real-life results of the Sofosbuvir (SOF)/Simeprevir(SIM) combination have been extensively reported in genotype 1-infected patients but there are few or no data regarding genotype 4-infected patients for the SOF/SIM or the SOF-Daclatasvir (DCV)combinations. In January 2015, more than 3003 patients of theFrench observational cohort ANRS CO22 HEPATHER were given thenew oral antivirals in 32 centers: we report the preliminary resultsof the Sofosbuvir-based combinations with DCV or SIM, with orwithout ribavirin (RBV), in Genotype 4-infected patients.Material and Methods:Demographics, history of liver disease werecollected at entry in the cohort. Clinical, adverse events, andvirological data were collected throughout treatment and post-treatment follow-up.

Fichiers et liens (1)

url

Find in HALAfficher

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather
Créateurs - sans rôle: H. Fontaine - Université de Montpellier, Institut de Recherche en Cancérologie de Montpellier - IRCM
C. Hezode - Inserm
F. Zoulim - Centre de Recherche en Cancérologie de Lyon
D. Samuel - Université Paris-Sud
M. Bourlière - Hôpital Saint Joseph
G. Haour - Sorbonne Université
C. Dorival-Mouly - Sorbonne Université
V. Leroy - Inserm
V. de Ledinghen - Hôpital Cardiologique du Haut-Lévêque
S. Lucier - Inserm
D. Larrey - Hôpital Saint Eloi
A. Tran - Inserm
S. Metivier - Hôpital Purpan
Y. Benhamou - Pitié-Salpêtrière Hospital
I. Hubert-Fouchard - Centre Hospitalier Universitaire d'Angers
F. Habersetzer - Inserm
P. Marcellin - Hôpital Beaujon
P. Mathurin - Hôpital Claude Huriez
Laurent Alric - Université Toulouse III - Paul Sabatier
J. -P. Bronowicki - Université de Lorraine
D. Guyader - Université de Rennes
V. Loustaud-Ratti - Hôpital Dupuytren
A. Minello - CHU Dijon Bourgogne
G. Riachi - Centre d'Investigation Clinique [CHU Rouen]
I. Rosa - Hôpital Intercommunal de Créteil
M. Simony - Agence Nationale de Recherches sur le Sida et les Hépatites Virales
A. Diallo - Agence Nationale de Recherches sur le Sida et les Hépatites Virales
F. Carrat - Sorbonne Université
S Pol - Université Paris Cité
Colloque: The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver (Vienne, Austria, 22/04/2015)
Identifiants: 99150267909311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM; Cell souches plasticité cellul régénérat tissulaire immuno des maladies inflamm - IRMB
Langue: English
Type de ressource: Conference poster
Champs locaux: hal-01162770